In this article, we report two cases of acute toxic leukoencephalopathy to highlight this acute clinicoradiological syndrome as an important, although uncommon, consideration in the undifferentiated comatose patient who fails to wake following drug overdose or has unexplained neurology with a history of drug exposure. We then review the current literature and discuss potential differential diagnoses in this setting, along with proposed treatments for this condition. The cases presented demonstrate a more fulminant onset than previously welldefined acute toxic leukoencephalopathy subtypes and highlight the prognostic importance of magnetic resonance imaging in diagnosing a condition from which significant functional recovery seems possible.
Acute toxic leukoencephalopathy is a clinicoradiological syndrome with diffuse white matter dysfunction secondary to structural damage of myelin. It is an uncommon diagnosis that remains an important consideration in the undifferentiated comatose patient who fails to wake following drug overdose, or has unexplained neurology with a history of drug exposure. The term covers a wide variety of exposures and clinical presentations (see Table 1 ) 1 . White matter is generally diffusely and symmetrically involved on magnetic resonance imaging (MRI) 2 , but grey matter involvement can vary in distribution and extent 1 . This anatomical variation may depend on the toxin, the route of exposure, the presence of other injurious factors, or with the severity of the white matter changes. Known causes include radiation exposure, therapeutic drugs (e.g. tacrolimus, interferon, cisplatin, fluorouracil, antineoplastic agents), drugs of abuse (toluene, methylbenzene, ethanol, heroin, alcohol), and environmental toxins (carbon monoxide, arsenic, carbon tetrachloride, toluene and other solvents). There is some overlap with other acute white matter disorders such as Posterior Reversible Encephalopathy Syndrome (PRES), however there is clear radiological distinction on MRI that is likely due to the proposed differing aetiologies 3 . Permission to report on the following two cases was obtained from the patients' next of kin.
CASE ONE
A 23-year-old male was found unresponsive in his room with a Glasgow Coma Scale score (GCS) of 4 (E1M2V1). When last seen more than 24 hours earlier, he had appeared well, with no abnormal neurology or behaviour. He was mildly hypoxic, febrile (39°C), and was making abnormal movements. Pupils were equal and reactive, and there was no meningism. He was intubated and received phenytoin and ceftriaxone.
Collateral history from family was significant for past amphetamine addiction, possible anabolic steroid use and reported exposure to non-toluene solvents. He had been prescribed mirtazapine and quetiapine for bipolar affective disorder.
Bloods tests suggested rhabdomyolysis (CK 50,200 U/l) with deranged liver function tests (bilirubin <4 µmol/l, AST 1690 U/l, ALT 927 U/l), mild coagulopathy (INR 1.8) and renal impairment (creatinine 343 µmol/l). Though the urine drug screen was suggestive of amphetamine exposure further confirmatory tests were negative. Non-contrast computed tomography of his brain was normal. A plain chest X-ray suggested right lower lobe aspiration pneumonitis. All cultures, including a lumbar puncture and viral polymerase chain reaction on cerebrospinal fluid analysis, were negative.
He received treatment for presumed central nervous system infection, pulmonary aspiration and a left tensor fascia lata compartment syndrome. Sedation was ceased on day one and a GCS of 6 (E3 V1t M2) was noted, with brisk reflexes bilaterally, upgoing plantars, sustained clonus and extensor posturing. Electroencephalography revealed a diffuse slow wave encephalopathy with no seizure activity. A metabolic screen was normal. MRI revealed diffuse white matter changes (Figures 1 and 2 ). In light of these findings and the alleged history of substance abuse, a diagnosis of acute toxic leukoencephalopathy was made and he was commenced on vitamin C, vitamin E and coenzyme Q10. Possible causative toxins were amphetamines, solvents, or the combination of mirtazapine and quetiapine. His GCS fluctuated from 3 to 7, with prominent sympathetic storming (fever, tachycardia, diaphoresis and tachypnoea). The patient was discharged to the ward on day 12 with a tracheostomy in situ, a stable GCS of 7 (E4 V1t M2), and persistent spastic quadriparesis. With intensive allied health input, he regained the ability to interact and maintain simple conversation, although he required assistance with transfers and mobility to complete activities of daily living. This improvement was ongoing at his time of discharge to a rehabilitation facility eight months after his initial admission to our hospital.
CASE TWO
A 26-year-old man was found with a GCS of 3, hypoxic and hypoglycaemic (blood glucose 1.6 mmol/l). Oxygen saturations were 88% on 100% oxygen. He was intubated and ventilated after no improvement in GCS with administration of 50% dextrose and intravenous naloxone. On examination, he had a low grade fever (37.6°C), pupils of 3 mm that were equal and reactive to light, intact corneal, cough and gag reflexes and no meningism.
Collateral history from family suggested clonazepam and oxycodone ingestion. He had otherwise been well up to this acute presentation, but had a background of post-traumatic stress disorder, opioid and benzodiazepine dependence and previous polypharmacy overdoses. Current prescription medi- cations were quetiapine, clonazepam, mirtazapine and sertraline.
Computed tomography of his brain demonstrated bilateral hypodensities in the globus pallidus, posterior limbs of the internal capsule extending into the left anterior capsule, both cerebellar hemispheres and left temporal lobe.
On day one after cessation of sedation, the patient began extensor posturing and exhibited sympathetic storming with spastic quadriparesis. Metoprolol, clonidine and chlorpromazine were commenced with limited effect. MRI showed diffuse leukoencephalopathy and hypoxic-ischaemic injury (Figures 3 and  4 ). His intensive care stay was complicated by aspiration pneumonia and a central line-associated bloodstream infection. He was discharged to the ward on day 12 with a GCS of 7 (E4V1tM2) and a tracheostomy in situ.
Over the following weeks, he demonstrated no neurological improvement, but developed an acute bowel obstruction resulting in institution of treatment limitations following family discussion. The patient died on day 60 of his hospital admission.
AETIOLOGY
The aetiology of acute toxic leukoencephalopathy remains uncertain. Direct cellular toxicity of a drug or its contaminants is suspected. The spectrum of clinicoradiological phenotypes reflects different cellular susceptibilities and pathophysiological mechanisms.
In Wolters' case series of heroin spongiform leukoencephalopathy (HSLE), many contaminants were identified but none have been consistently involved 2 .
Opiates may be neurotoxic, particularly heroin which has higher affinity to mu receptors that are more concentrated in the cerebellum and limbic system 5 . However, newer synthetic opioids do not share this affinity and therefore cannot fully explain the observed posterior predominance of HSLE 5 . Synergy of toxins, e.g. cocaine and heroin, and sensitisation, through repeated exposure or a threshold effect, is proposed to explain the development of neurology after years of asymptomatic drug abuse 5 . Cellular injury may then induce immune-mediated damage. Hypoxia may prime cells to toxic injury or accentuate an insult from a toxin or vice versa 6 . Mitochondria may be the target of toxicity or experience resultant dysfunction based on magnetic resonance spectroscopy findings that suggest conversion to cellular anaerobic activity.
An alternative to the cell toxicity hypothesis is vascular injury with secondary white matter damage and injury to oligodendrocytes such that myelin production is interrupted 2 . Vascular effects may be more prominent in cocaine-or amphetamine-related cases 2, 7 .
Lack of a consistent association between drug dosage and frequency of use raises the possibility of individual variance in susceptibility to toxic white matter damage that may be genetically based. Genetic susceptibility to delayed post hypoxic leukoencephalopathy (DPHL) is also proposed, based on the frequency of mild-moderate hypoxia and the contrasting infrequency of the condition 1,8-10 . A toxin can unmask an underlying latent disease. A case of leukoencephalopathy was precipitated by phenytoin use in a patient with a methylenetetrahydrofolate reductase enzyme deficiency 11 . Methylenetetrahydrofolate reductase deficiency usually presents in childhood without a precipitant. Deficiencies in arylsulfatase A enzyme were described in cases of DPHL associated with carbon monoxide exposure, however cases of this type of leukoencephalopathy have occurred where enzyme levels are normal [8] [9] [10] . The mechanism of PRES is poorly understood. It was previously believed that hypertension resulted in autoregulatory vasoconstriction with subsequent hypoperfusion and oedema. However, the belief that autoregulatory limits are surpassed leading to a breakthrough of the blood brain barrier has gained popularity 12 . Endothelial injury and activation with subsequent vasoconstriction has been proposed for infection-and drug-related cases 12 .
DIFFERENTIAL DIAGNOSIS
MRI is required for reliable diagnosis of leukoencephalopathy and should be considered in patients who have a level of consciousness that is inadequately explained by history, including the drug ingested, failure to respond to antagonists or persistent neurological deficit. Computed tomo-graphy may be normal except at the more severe end of the spectrum, where it is likely to signify a poor prognosis.
In the context in which it is likely to be encountered in intensive care, the initial differential diagnoses are those for coma, particularly residual drug effect and hypoxic-ischaemic encephalopathy. When white matter changes are noted on MRI then the differential diagnoses are for a leukoencephalopathy as shown in Table 2 2, 13, 14 .
Weber proposed a case definition in 1998 to aid in diagnosis of HSLE: history of inhaling heroin, a period of heroin withdrawal, cerebellar signs and symptoms, symmetrical lesions of the white matter of the cerebellum, cerebellar and cerebral peduncles, posterior limb of internal capsule, and the centrum semiovale with sparing of the U fibres 15 . Variation on typical HSLE has been reported in the route of exposure, type of opiate, coingestion of other illicit substances, anatomical areas involved, as well as presentations with a more acute and fulminant course that lacks definable stages 3,5-7,10,16-19 .
DPHL has a different time course and no consistent relationship to toxin exposure. A subtype due to carbon monoxide toxicity occurs up to 40 days post exposure and affects the basal ganglia and frontal lobes, with subsequent onset of delayed neurological sequelae 8, 9 . When a hypoxic insult is combined with drug overdose, the patient may be admitted to the psychiatric unit following apparent recovery from their drug-related coma, only to subsequently deteriorate with severe catatonia and akinetic mutism 8, 19, 20 . This deterioration may be erroneously attributed to the toxic insult and the effect of 'coasting' (where progressive toxicity occurs after the withdrawal of the offending agent), rather than DPHL.
Either occupational or recreational exposure to solvents, particularly toluene, is known to cause multifocal demyelination at autopsy, perhaps due to a direct toxic effect on myelin, although the onset of neurological signs is slow and progressive 2 . The cerebellum seems to be primarily affected 21 and effects appear to be dose-and duration-dependent 22, 23 . Recovery is variable, however, despite the cessation of solvent abuse and the absence of clinical progression, changes are still noted at autopsy 21 . Abstinence from petrol sniffing can result in significant clinical improvement, however, this is not seen after chronic glue sniffing 23 .
PRES is a better known syndrome that is associated with many underlying conditions such as preeclampsia, autoimmune disease and hypertension, as well as toxins such as immunosuppressant therapy and chemotherapy. Blood pressure may be normal at symptom onset in 20% to 30% of patients 12 . Laboratory evidence of endothelial injury (thrombocytopenia, elevated lactate dehydrogenase, schistocytes) is increasingly recognised 12 . Acute disseminated encephalomyelitis is an important differential, particularly in children where the neurology progresses over hours to days. Onset follows an infection or vaccination that leads to immune-mediated damage via molecular mimicry or destruction of the blood brain barrier by the pathogen with myelin antigen release 24 .
TREATMENT
Toxic leukoencephalopathy is a heterogenous diagnostic group with varying aetiology and pathophysiology. Supportive care and rehabilitation remain the mainstay of therapy. Cessation and avoidance of the causative agent is important, as rapid relapse upon re-exposure has been reported 7 . Attempts at treating DPHL with plasmapheresis and immunomodulation have not been successful in case studies 1 . Hyperbaric oxygen is of debatable efficacy in the carbon monoxide-induced variant of DPHL.
Therapy with antioxidants such as coenzyme Q10 and high dose vitamin C and E have been reported as successful in limited case studies 20, 25, 26 . It is theorised that coenzyme Q10 limits permanent damage by accepting electrons from the mitochrondrial oxidation respiratory chain 20 . Cases of clinical improvement have occurred without its use 19 . Due to their favourable side-effect profile, the risk-benefit ratio falls in favour of administration of antioxidants.
PRES requires supportive care (e.g. antiepileptic drugs), management of hypertension, and consideration of the causative process with treatment of infection and any underlying disease.
OUTCOME
The clinical severity of the leukoencephalopathy is thought to correlate well with the severity and anatomical extent of the white matter damage on MRI 2 . However, the correlation with outcome is not defined and there are no large longitudinal studies. One case series of toxic leukoencephalopathy found no correlation between severity of MRI markers on initial MRI (diffusion weighted image extent, percentage of apparent diffusion coefficient decrease, fluid attenuated inversion recovery extent) and outcome 3 . There was moderate correlation with initial MRI findings and the residual abnormality on followup MRI. Cystic degeneration has been described on follow-up MRI 10, 16 .
Outcome may vary widely between the different clinicoradiological phenotypes. For example, some deaths are reported from DPHL, however, most patients have some recovery with persistent cognitive and neurological disability 1 . Carbon monoxide variant reports 60% to 75% recovery within a oneyear period 1 . Mortality for HSLE varies from 24% to 48% 1, 4 . Recovery of function in survivors is also highly variable, but complete recovery is rare. Ataxia is a commonly reported residual deficit of HSLE despite an otherwise functional existence.
Variation from the classic three stage HSLE is reported after acute opiate exposure with rapid onset of profound coma 5, 6, 16, 17 . This pattern appears to be more common in children 6, 17, 18 , where a more rapid and complete recovery is seen, perhaps due to neuronal plasticity 17 .
In an analysis of patients who received chemotherapy prior to bone marrow transplant, those who developed acute toxic leukoencephalopathy had a mortality rate of 73% due to neurotoxicity, versus 18% for those who suffered PRES 27 . This may suggest that the outcome is related to the underlying pathophysiological cause, as mentioned above.
The natural course of PRES is usually of full clinical recovery within days to weeks with adequate management however, permanent ischaemia and haemorrhage can occur with delay in diagnosis and treatment 12 .
CONCLUSION
Acute toxic leukoencephalopathy remains an important, albeit uncommon, diagnosis to consider in the unconscious intensive care patient. Our cases demonstrate a more fulminant course than previously well-defined toxic leukoencephalopathy subtypes, although similar paediatric cases have been described in the literature. Although no unifying toxin was identified as the precipitant in our cases, the clinical presentation and features had significant overlap. It is believed that the severity of hypoxic and hypoglycaemic injury was responsible for the lack of recovery in our second case. Our cases highlight the prognostic importance of MRI in diagnosing a condition for which significant functional recovery seems possible.
